Invivyd (IVVD) announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR Study Group. The SPEAR Study Group was launched earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd announces updated NCCN Clinical Practice Guidelines for COVID-19
- Invivyd Launches SPEAR Study for Long COVID Therapy
- Invivyd forms SPEAR study group to assess therapy for long-COVID
- Invivyd’s VYD2311: Promising Phase 1/2 Trial Results and Strategic Positioning Support Buy Rating
- Invivyd Announces Positive Phase 1/2 Trial Results